The US health regulator has provided its final approval to the drug firm Zydus Cadila for marketing anti-diabetic Glyburide tablets in the American market.

Zydus Cadila has said in a statement that the group has got final approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 1.25, 2.5 and 5 mg.

The production of Glyburide will be done at the group’s formulations manufacturing facility at Baddi (Himachal Pradesh).

Read EquityPandit’s Nifty Pharma Outlook for this week